慢性肾脏病患者亚临床甲状腺功能减退症的研究进展

摘要
图/表
参考文献(33)
相关文章 (15)

全文: PDF (0 KB) HTML (37 KB)
输出: BibTeX | EndNote (RIS)

摘要

慢性肾脏病（CKD）的患病率与发病率日益增长，已成为全球面临的严重公共卫生问题之一。在CKD 病程进展中，常伴随甲状腺素合成、分泌、分解及代谢异常，表现为甲状腺功能减退症，其中以低T3 综合征（LT3S）及亚临床甲状腺功能减退症（SCH）常见。目前研究结果表明，CKD 与甲状腺功能减退症可能互为影响，CKD 可引起甲状腺功能减退症，甲状腺功能减退症亦会导致CKD患者肾功能下降。CKD 和终末期肾病（ESRD）中SCH 可能与较高的心血管发病率和全因死亡率有关，是其不良结局的预测因素。但目前关于CKD患者SCH 流行病学调查相关研究较少，且甲状腺素替代治疗的安全性及有效性迄今为止仍存在争议。本文就CKD 与甲状腺功能减退症相互作用机制、CKD患者SCH的患病率及甲状腺素替代治疗对于CKD患者预后影响的研究进展进行阐述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谭妮
	石磊

关键词 ：慢性肾脏病, 终末期肾病, 亚临床甲状腺功能减退症, 甲状腺功能减退症, 甲状腺素替代治疗

Abstract：The prevalence and incidence of chronic kidney disease (CKD) is increasing,which has become one of the serious public health problems in the world.During the progression of CKD,thyroid hormone synthesis,secretion,decomposition and metabolism are often accompanied by abnormalities,characterized by hypothyroidism,which is common in low T3 syndrome (LT3S) and subclinical hypothyroidism (SCH).The research results show that CKD and hypothyroidism may influence each other.CKD can cause hypothyroidism,and hypothyroidism can also lead to the decrease of renal function in patients with CKD.In CKD and end-stage renal disease (ESRD),SCH may be associated with higher cardiovascular morbidity and all-cause mortality,which is a predictor of adverse outcomes.However,there are fewer studies on the SCH epidemiological investigation in patients with CKD.Up to now,the safety and efficacy of thyroxine replacement therapy are still controversial.In this paper,the mechanism of interaction between CKD and hypothyroidism,the prevalence of SCH in patients with CKD,and the influence of thyroid replacement therapy on the prognosis of patients with CKD were described.

Key words： Chronic kidney disease End-stage renal disease Subclinical hypothyroidism Hypothyroidism Thyroid hormone replacement therapy

基金资助:湖北省恩施州第一批农业与社会发展科技指导性计划项目（恩州科业[2015]12号文件11号）

作者简介: 谭妮（1993-），女，湖北宣恩人，湖北民族大学临床内科学专业2018级在读硕士研究生，研究方向：肾脏病学

引用本文:

谭妮；石磊. 慢性肾脏病患者亚临床甲状腺功能减退症的研究进展[J]. 中国当代医药, 2021, 28(7): 29-32.
TAN Ni；SHI Lei. Research progress of subclinical hypothyroidism in patients with chronic kidney disease. 中国当代医药, 2021, 28(7): 29-32.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I7/29

[1]	Khatiwada S，Rajendra KC，Gautam S，et al.Thyroid dysfunction and dyslipidemia in chronic kidney disease patients[J].BMC Endocr Disord，2015，15：65.
[2]	Shantha GP，Kumar AA，Bhise V，et al.Prevalence of Subclinical Hypothyroidism in Patients with End-Stage Renal Disease and the Role of Serum Albumin：A Cross-Sectional Study from South India[J].Cardiorenal Med，2011，1（4）：255-260.
[3]	Ng YY，Wu SC，Lin HD，et al.Prevalence of clinical and subclinical thyroid disease in a peritoneal dialysis population[J].Perit Dial Int，2012，32（1）：86-93.
[4]	Rhee CM，Brent GA，Kovesdy CP，et al.Thyroid functional disease：an under-recognized cardiovascular risk factor in kidney disease patients[J].Nephrol Dial Transplant，2015，30（5）：724-737.
[11]	曹慧霞，丁士新，马旭，等.非透析慢性肾脏病患者亚临床甲状腺功能减退症患病情况及其危险因素研究[J].中国全科医学，2012，15（26）：3012-3014.
[27]	乔妍，方敬爱.腹膜透析患者亚临床甲状腺功能减退与左心功能的相关性分析[J].中国中西医结合肾病杂志，2018，19（5）：415-417.
[33]	Rhee CM.Thyroid disease in end-stage renal disease[J].Curr Opin Nephrol Hypertens，2019，28（6）：621-630.
[5]	Rhee CM，Ravel VA，Streja E，et al.Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort[J].J Clin Endocrinol Metab，2016，101（11）：4054-4061.
[6]	Targher G，Chonchol M，Zoppini G，et al.Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis[J].Clin Chem Lab Med，2009，47（11）：1367-1371.
[7]	Cuna V，Menghi V，Comai G，et al.Functional Abnormalities and Thyroid Nodules in Patients with End-stage Renal Disease[J].In Vivo，2017，31（6）：1203-1208.
[8]	Lo JC，Chertow GM，Go AS，et al.Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease[J].Kidney Int，2005，67（3）：1047-1052.
[9]	Rhee CM，Kalantar-Zadeh K，Streja E，et al.The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease[J].Nephrol Dial Transplant，2015，30（2）：282-287.
[10]	Chonchol M，Lippi G，Salvagno G，et al.Prevalence of subclinical hypothyroidism in patients with chronic kidney disease[J].Clin J Am Soc Nephrol，2008，3（5）：1296-1300.
[12]	Chandra A.Prevalence of hypothyroidism in patients with chronic kidney disease：a cross-sectional study from North India[J].Kidney Res Clin Pract，2016，35（3）：165-168.
[13]	Ng YY，Lin HD，Wu SC，et al.Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients[J].Thyroid，2013，23（5）：552-561.
[14]	Rhee CM，Alexander EK，Bhan I，et al.Hypothyroidism and mortality among dialysis patients[J].Clin J Am Soc Nephrol，2013，8（4）：593-601.
[15]	Rhee CM，Kim S，Gillen DL，et al.Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients[J].J Clin Endocrinol Metab，2015，100（4）：1386-1395.
[16]	Fekete C，Lechan RM.Central regulation of hypothalamicpituitary-thyroid axis under physiological and pathophysiological conditions[J].Endocr Rev，2014，35（2）：159-194.
[17]	Geng J，Hu T，Wang B，et al.Thyroid stimulating hormone levels and risk of coronary heart disease in patients with type 2 diabetes mellitus[J].Int J Cardiol，2014，174（3）：851-853.
[18]	Li LZ，Hu Y，Ai SL，et al.The relationship between thyroid dysfunction and nephrotic syndrome：a clinicopathological study[J].Sci Rep，2019，9（1）：6421.
[19]	Schomburg L.Selenium，selenoproteins and the thyroid gland：interactions in health and disease[J].Nat Rev Endocrinol，2011，8（3）：160-171.
[20]	Wiederkehr MR，Kalogiros J，Krapf R.Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients[J].Nephrol Dial Transplant，2004，19（5）：1190-1197.
[21]	Basu G，Mohapatra A.Interactions between thyroid disorders and kidney disease[J].Indian J Endocrinol Metab，2012，16（2）：204-213.
[22]	Rodríguez-Gómez I，Banegas I，Wangensteen R，et al.Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats[J].J Endocrinol，2013，216（1）：43-51.
[23]	Karanikas G，Schütz M，Szabo M，et al.Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy[J].Am J Nephrol，2004，24（1）：41-45.
[24]	Collins AJ，Kasiske B，Herzog C，et al.Excerpts from the United States Renal Data System 2004 annual data report：atlas of end-stage renal disease in the United States[J].Am J Kidney Dis，2005，45（1 Suppl 1）：A5-7，S1-280.
[25]	Afsar B，Yilmaz MI，Siriopol D，et al.Thyroid function and cardiovascular events in chronic kidney disease patients[J].J Nephrol，2017，30（2）：235-242.
[26]	Go AS，Chertow GM，Fan D，et al.Chronic kidney disease and the risks of death，cardiovascular events，and hospitalization[J].N Engl J Med，2004，351（13）：1296-1305.
[28]	Kang EW，Nam JY，Yoo TH，et al.Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients[J].Am J Nephrol，2008，28（6）：908-913.
[29]	Shin DH，Lee MJ，Kim SJ，et al.Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism[J].J Clin Endocrinol Metab，2012，97（8）：2732-2740.
[30]	Bajaj S，Purwar N，Gupta A，et al.Prevalence of hypothyroidism in diabetic kidney disease and effect of thyroid hormone replacement on estimate glomerular filtration rate[J].Indian J Endocrinol Metab，2016，20（6）：795-798.
[31]	Tang W，Chen Q，Chen，et al.Favorable effect of levothyroxine on nutritional status of patients with stage 3-4 chronic kidney disease patients[J].Acta Endocrinol（Buchar），2018，14（3）：338-345.
[32]	Deng X，Tang C，Wu J，et al.Changes of nutritional status and the variations of serum indicators of patients with chronic kidney disease accompanied by hypothyroidism taking thyroid hormone replacement therapy as the therapeutic models[J].Saudi J Biol Sci，2019，26（8）：2091-2095.